HIV Clinical Trials

Journal

Publication Venue For

  • Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: Results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.  17:72-77. 2016
  • Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.  16:89-99. 2015
  • Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in hiv-positive individuals with metabolic complications.  14:303-312. 2013
  • Effect of darunavir on lipid profile in HIV-infected patients.  13:256-270. 2012
  • Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Week-192 overall and subgroup analyses from STARTMRK.  13:228-232. 2012
  • Aging and HIV infection: A comparison between older HIV-infected persons and the general population.  11:100-109. 2010
  • Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.  11:125-132. 2010
  • Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.  10:181-192. 2009
  • Electrocardiogram abnormalities with Atazanavir and Lopinavir/Ritonavir.  10:328-336. 2009
  • Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).  10:343-355. 2009
  • Novel methodology for antiretroviral quantitation in the female genital tract.  10:193-199. 2009
  • Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/ emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).  10:160-167. 2009
  • Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.  10:41-47. 2009
  • Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) protocol 353.  9:115-125. 2008
  • Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.  9:91-102. 2008
  • Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals.  8:173-181. 2007
  • Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood..  7:263-269. 2006
  • Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood.  7:263-269. 2006
  • Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube.  5:288-293. 2004
  • A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.  4:287-300. 2003
  • Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.  2:193-199. 2001
  • Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.  2:460-465. 2001
  • International Standard Serial Number (issn)

  • 1528-4336
  • Electronic International Standard Serial Number (eissn)

  • 1945-5771